Our employees are committed to providing families across the country with delicious, fresh berries, and we are doing everything we can to ensure that they and their families stay safe and have their food needs met during this time.

OXNARD, Calif. (PRWEB)
May 26, 2020

Reiter Affiliated Companies (RAC), the largest fresh multi-berry producer, reinforces commitment to supporting the health, happiness and wellbeing of their farmworker community as they continue working to keep food on America’s tables during the coronavirus pandemic.

“During these trying times, farmworkers’ contributions are more critical than ever,” said Ana Martinez, Wellbeing Manager for RAC. “Our employees are committed to providing families across the country with delicious, fresh berries, and we are doing everything we can to ensure that they and their families stay safe and have their food needs met during this time.”

Recognizing proper nutrition is key to health and the rising stress associated with recent shopping trends, Sembrando Salud is collaborating with Food Banks across California to provide fresh food.

“Food Share is proud to partner with Sembrando Salud and Reiter to provide fresh produce to farmworkers in Ventura County,” said Monica White, Food Share’s President & CEO. “Farmworkers provide an essential service in our community. We are happy to be a part of ensuring that they, too, benefit from the healthy fresh foods that their hard work enables us all to enjoy.”

Since the start of the pandemic, Sembrando Salud has distributed food to more than 7,000 farm workers in the regions where RAC operates, and will continue to coordinate these distributions for as long as the need exists.

Community partners include Ventura County FoodShare, SEEAG, Del Monte Produce, VC Local Love Project, Feeding the Frontline Initiative, Food Bank of SB County, Second Harvest Food Bank of Santa Cruz County and Food Bank of Monterey County.

As a family-owned farming company, RAC is passionate about the wellbeing of their farmworker community. RAC hopes that through taking steps to ease employees’ day-to-day burdens, they will have more time and energy to focus on their health and wellness for themselves and their families.

Sembrando Salud, RAC’s comprehensive health and wellness program, has dedicated itself to helping employees improve their overall wellbeing since 2009.

To learn more about Reiter Affiliated Companies, please visit: http://www.berry.net

About Reiter Affiliated Companies

Reiter Affiliated Companies (RAC) is the largest fresh multi-berry producer in the world, growing Driscoll’s proprietary varieties of strawberries, raspberries, blueberries, and blackberries year round in the United States, Baja California, Central Mexico, Portugal, Morocco, Canada and Peru.

The Reiter family began farming in the San Francisco Bay Peninsula and by the turn of the century had migrated south into Watsonville and the Santa Clara Valley. By the late 1970’s, operations expanded into Southern California where the headquarters is today. The company values of Honesty, Fairness and Respect line the corridors of every office, guiding and leading business principles and decisions. Those decisions have resulted in the organization’s position as an industry leader, adopting health and wellbeing programs, opening primary health clinics and partnering with local organizations to improve the quality of life for the farmworker community.

Share article on social media or email:

Neil Langberg & Nancy Linn drive global RP awareness and accelerate research.

It is especially gratifying to be working with the internationally-recognized center of excellence at the University of Pennsylvania and the world-renowned leaders in the conduct of clinical and translational research

PHILADELPHIA (PRWEB)
May 26, 2020

The Relapsing Polychondritis (RP) Foundation has announced a generous gift to establish the Penn Relapsing Polychondritis Fund, which will support a unique partnership between the University of Pennsylvania RP Program and the National Institutes of Health (NIH) sponsored Vasculitis Clinical Research Consortium (VCRC).

With support from Race for RP, Nancy Linn and Neil Langberg, the Penn Relapsing Polychondritis Fund will expand these exceptional programs that will improve care for patients with RP. RP is an understudied, underdiagnosed, and undertreated systemic inflammatory disease that causes the body to attack its own cartilage and can prove fatal if left untreated.

“The absence of any clinical trials or other high-quality clinical research in relapsing polychondritis has greatly hampered advancing therapies and outcomes for patients with this rare disease,” says Dr. Peter A. Merkel, MD, MPH, Chief, Division of Rheumatology at University of Pennsylvania and principal investigator of the VCRC.

“As a patient, I am extremely pleased the Foundation has implemented its plan to support research to advance a cure for relapsing polychondritis,” said Nancy Linn, Chair of the Relapsing Polychondritis Foundation. She added, “It is especially gratifying to be working with the internationally-recognized center of excellence at the University of Pennsylvania and the world-renowned leaders in the conduct of clinical and translational research.”

“The Penn RP Program represents the RP Foundation’s unwavering commitment to powerful research initiatives that improve patient care and relentlessly advance the path to a cure,” said David Bammert, President of the Relapsing Polychondritis Foundation. “It also provides our philanthropic partners with the unprecedented opportunity to support substantive RP research programs as well as the Foundation’s awareness and educational initiatives.”

The Penn RP Program will allow researchers to pursue important projects, including the development of a world-class referral center to examine the impact of the microbiome on RP disease activity. Eligible patients will be enrolled in a longitudinal study using the existing infrastructure of the VCRC, which is comprised of an integrated group of academic medical centers, patient support organizations, and clinical research resources dedicated to conducting clinical research, with participating centers around the United States and Canada.

At the University of Pennsylvania, patients with RP will have the opportunity to be evaluated by multiple subspecialties in a coordinated patient-centered manner. Along with Dr. Merkel, patient evaluations will be led by Dr. Shubhasree Banerjee, a faculty member in the Penn Division of Rheumatology who received prior advanced training in the evaluation and management of RP.

#     #     #

About Relapsing Polychondritis

Relapsing polychondritis (RP) is a debilitating and sometimes fatal systemic inflammatory disease characterized by recurrent inflammation of cartilage and other tissues throughout the body. The disease affects multiple organs, particularly cartilaginous structures such as the ears, nose, airways and joints as well as eyes, skin, heart valves and brain. The cause of RP is unknown and there is no cure for RP. For more information, visit https://bit.ly/RP_Poster.

About Relapsing Polychondritis Foundation

The RP Foundation’s purpose is to facilitate education, awareness and research initiatives that improve the quality of life for patients with RP. For more information, visit https://www.polychondritis.org.

About Race for RP

Race for RP supports research and awareness programs for relapsing polychondritis and related diseases. For more information, visit RaceforRP.org or Facebook.com/raceforrp/. Follow Race for RP on Instagram, @RaceforRP.

About the Penn Vasculitis Center and the Vasculitis Clinical Research Consortium        

Under the direction of Dr. Peter A. Merkel, the Penn Vasculitis Center is an internationally recognized center of excellence for the care and management of patients with all forms of vasculitis. The Center conducts cutting-edge clinical and translational research in vasculitis. The Center also hosts the Vasculitis Clinical Research Consortium, the world’s foremost clinical research infrastructure for vasculitis, and a founding member of the NIH Rare Diseases Clinical Research Network, an integrated group of academic medical centers and patient support organizations dedicated to conducting clinical research. The VCRC conducts clinical trials, large observational studies, biomarker and genomic investigations, epidemiologic analyses, and other forms of research in over 100 centers worldwide.

Share article on social media or email:

Genedata Biologics is a perfect fit for our approach, because… we anticipate that the platform will be able to handle our bispecific engineering and TCR discovery and optimization workflows without any customization

SAN FRANCISCO (PRWEB)
May 26, 2020

Genedata, the leading provider of enterprise software solutions for biopharmaceutical R&D, today announced that Gritstone Oncology, Inc., a clinical-stage biotechnology company developing cancer immunotherapies, including a portfolio of T-cell receptor (TCR)-mimetic bispecific T cell engagers and TCR-based therapeutics, has implemented Genedata Biologics® within their R&D organization.

“Genedata Biologics is a perfect fit for our approach, because it comes with built-in functionalities that support the specialized immuno-oncology applications we require. For instance, we anticipate that the platform will be able to handle our bispecific engineering and TCR discovery and optimization workflows without any customization,” said Jonah Rainey, Ph.D., Head of Antibody Therapeutics at Gritstone Oncology. “We are also looking forward to further automating our R&D processes and increasing throughput in our immunotherapy discovery programs.”

Gritstone Oncology will use Genedata Biologics, a purpose-built enterprise platform for biopharma R&D, to design, engineer, and validate next-generation antibody therapeutic molecules such as bispecific antibodies. Additionally, it will be used for advancing the R&D for multiple programs targeting cancer testis antigens and common mutations resulting in neoantigens. Genedata Biologics integrates all R&D workflows in a common workspace, giving the Gritstone teams comprehensive and real-time access to all relevant R&D data. Using the platform, Gritstone will automate R&D workflows, including molecular biology, screening, engineering, cloning, expression, purification, and analytics processes.

Gritstone Oncology chose to operate Genedata Biologics as Software-as-a-Service (SaaS). This deployment option gives them an agile setup and increases operational efficiency, without the need to invest in the hardware and internal IT support required for an on-premise deployment.

“We are very pleased that Gritstone Oncology, an innovative leader in the field of personalized immunotherapies, has chosen Genedata to support their complex R&D processes,” said Othmar Pfannes, Ph.D., CEO of Genedata. “The Genedata Biopharma Platform is a game changer in biopharma R&D. We help companies stay at the forefront of innovation with our continual investment in developing the platform to address new requirements, such as for TCRs, CAR Ts or novel cancer vaccines. Our goal is to digitalize and streamline all R&D workflows so that our partners can fully exploit the value of their data as they hunt for the next generation of therapies.”

About Genedata

Genedata transforms data into intelligence with innovative software solutions and domain-specific consulting services that automate complex, large-scale experimental processes and enable organizations to maximize the ROI in their R&D, spanning early discovery all the way to the clinic. Founded in 1997, Genedata is headquartered in Switzerland with additional offices in Germany, Japan, Singapore, the UK, and the US.

http://www.genedata.com

LinkedIn | Twitter | YouTube

Contact

Miles Fisher-Pollard

Genedata

Public Relations

Phone: +41 61 511 85 61

pr@genedata.com

Disclaimer

The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company’s products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

All product and service names mentioned are the trademarks of their respective companies.

Share article on social media or email:

Five Acres launches its HOPE line to help families and individuals seeking mental health support.

The number of referrals being received by our community service programs is on the rise due to the mental stress of the pandemic.

ALTADENA, Calif. (PRWEB)
May 26, 2020

Now with the U.S. highest unemployment rate due to the coronavirus, people are struggling financially, experiencing food insecurity, and facing mental health challenges like depression, anxiety and suicidal thoughts. Altadena-based foster care/adoption and mental health provider, Five Acres has launched the HOPE line at 800-696-6793 or HOPE@5acres.org where individuals can call, text or email. The HOPE line staff helps people in need of support in mental health, prevention of child abuse, domestic violence, and families seeking to become foster resource families.

“The number of referrals being received by our community service programs is on the rise due to the mental stress of the pandemic,” said Five Acres CEO Chanel Boutakidis, who also expressed concern for the children who are experiencing abuse behind closed doors and have no means of reporting it to a trusting adult like a teacher, school counselor, or peer.

According to the Los Angeles Department of Children and Family Services, on average, the county’s Child Protection Hotline received about 1,000 daily reports. In recent weeks, however, there has been a decline in calls of up to 50 percent.

The agency’s community-based services team is available now to assist with basic needs resources, assessing abuse and reporting it, and starting the process for additional Five Acres services. While the HOPE line is not a 24/7 crisis line, the agency’s staff will reply within one business day to all texts or calls to 1-800-696-6793 or emails to HOPE@5acres.org requesting help.

To learn more about Five Acres and to support the agency’s efforts, visit 5acres.org.

# # #

For media: Additional images and social media messages can be downloaded at here: https://5acres.org/five-acres-hope-line

About Five Acres

Since 1888, Five Acres has protected the most vulnerable members of our community: children. Serving more than 10,000 children and family members annually across six counties, including Los Angeles, Ventura, Riverside, San Bernardino, Orange, and Kern, Five Acres strives for permanency—a permanent, loving home—for all children in their care. The three pillars of safety, well-being and permanency provide the framework for its programs and guide the way as the agency develops even more effective means of caring for children and families in crisis. Visit 5acres.org.

Share article on social media or email:

With the current restriction on travel due to the COVID-19 pandemic, this option enables studies to proceed without delay and facilitates an expedited trial process for sponsors developing drugs to address the current global crisis.

SCOTTSDALE, Ariz. (PRWEB)
May 26, 2020

VirTrial today announced a new service designed to enable virtual site monitoring visits in the clinical trials industry. The solution enables pharmaceutical sponsors and CROs to evaluate, qualify and routinely monitor research sites for studies without physical travel. The service is the industry’s first patent-pending virtual site monitoring solution.

Virtual Pre-Site includes delivery of HD live-streaming glasses that enable an on-site Clinical Research Coordinator (CRC) to provide a remote Clinical Research Associate (CRA) access to all aspects of the site virtually simply by walking through the site wearing the glasses. Everything in view of the study coordinator streams to the CRA’s computer screen so she/he can verify the site qualifies for, is trained for and is performing the study to protocol standards.

Virtual Pre-Site, which is powered by the VirTrial Virtual Care Management (VCM) platform, streamlines and standardizes the study startup and routine monitoring process while ensuring consistent information is being collected across all sites. Virtual Pre-Site’s secure, HIPAA-compliant platform enables the CRA to conduct video interviews with both the CRC and the PI to ensure they have the needed patients, appropriate experience, and time to conduct the study. By eliminating the need for CRAs to travel, Virtual Pre-Site reduces the time required for study monitoring and slashes associated time and costs.

“Pharmaceutical sponsors have shown intense interest in this solution due to its ability to cut costs and reduce the time required to evaluate and monitor research sites,” said Deric Frost, VP of Virtual Pre-Site. “With the current restriction on travel due to the COVID-19 pandemic, this option enables studies to proceed without delay and facilitates an expedited trial process for sponsors developing drugs to address the current global crisis.”

COVID-19 spurred a significant increase in Virtual Pre-Site inquiries to accommodate site monitoring for existing studies and to expedite study startups for COVID and other drug trials. Early adopters and innovative sponsors and CROs, however, recognized the value well before the pandemic.

“As a CRO in the vanguard of the movement towards decentralization and digitization of clinical research conduct, Biorasi was one of the first to recognize the value in the VirTrial Pre-Site model,” said Wayne Bowden, VP of Program Development at Biorasi. “Innovative approaches like these, which leverage the latest technologies, are what will continue to drive improvement in trial operations, not only in our current crisis but also well beyond it. These are the types of approaches that we are interested in, to continuously enable a better experience for our clients, and we are proud to be a partner with VirTrial in that mission.”

For more information on VirTrial’s Virtual Pre-Site service, visit http://www.virtualpresite.com.

About VirTrial

VirTrial is a bioscience technology company providing a stable, long-standing telemedicine platform to transform the clinical trial industry. The Virtual Care Management (VCM) program combines secure video, audio, chat and messaging allowing pharmaceutical companies and CROs to create patient centric Decentralized Clinical Trials (DCTs) by replacing some study visits with virtual visits. The vision is for 25-50% of visits to be conducted virtually creating a hybrid model. VirTrial apps and services are supported on any device (Android, Apple, tablet, phone, computer) and can be used by any site worldwide. They are hosted in a secure cloud-based environment and are HIPAA and GDPR compliant.

VirTrial enables greater accessibility to trials for patients, higher performance by clinical trial sites, and improved outcomes for pharmaceutical companies. Working together we can bring better medications to market more quickly.

To learn more about VirTrial, visit https://www.virtrial.com

Share article on social media or email:

Karen Havenstrite, CTO, Tangible Science

“Karen Havenstrite is brilliant at taking innovative ideas and bringing them to the market, as she did after completing her PhD in Chemical Engineering at Stanford and co founding Tangible Science,” commented Larraine Segil, Chair and CEO of The Exceptional Women Awardees Foundation

LOS ANGELES (PRWEB)
May 26, 2020

The Exceptional Women Awardees Foundation (EWA, Los Angeles CA) today announced that after interviews with multiple candidates, Karen Havenstrite, CTO and Co-Founder, Tangible Science, has been invited to join their Cohort of Women Leaders for the Spring 2020 Awards.

“Karen has the innovative genius to create original technology and commercialize it as she has done with Tangible Science,” commented Larraine Segil, Chair and CEO of The Exceptional Women Awardees Foundation. ” She is a committed leader and original thinker. She is brilliant at taking innovative ideas and bringing them to the market, as she did after completing her PhD in Chemical Engineering at Stanford and co-founding Tangible Science. These characteristics make her exactly the kind of entrepreneurial awardee for whom we search.”

Dr. Vic McCray, CEO of Tangible Science: “Karen is exceptional in every sense of the word. The intelligence, drive, creativity and grit that she has demonstrated is unparalleled. These traits combined with her willingness to take risk and find her own unique path have led her to excel at bringing new and innovative technologies to market.”

Tangible® Science strives to dramatically improve the contact lens experience for patients, eye care professionals, and contact lens manufacturers. Contact lens wearers often complain of discomfort and inconvenience, while eye care practitioners are often frustrated by their inability to provide a comfortable solution for their contact lens patients that lasts all day. We are a young, motivated and creative team of doers that saw this problem and wanted to do something about it.

For custom contact lens wearers, we have created an innovative family of products specifically for them, to add greater comfort, deposit resistance and convenience. For soft lens wearers, we have partnered with contact lens manufacturers to create a variety of daily disposable lenses featuring a reformulation of our polymer technology to further enhance comfort and wearability.

Learn more at https://tangiblescience.com/

The Exceptional Women Awardees Foundation (EWA) selects high potential, upper-career Exceptional Women from multiple industries, develops and mentors them with guidance and career redesign advice to propel them to sustainable success – one woman at a time. Their year-long program enables the EWA to be connected for life to their ever-expanding EWA global network, as their fellow women leaders move into positions of significance.

Learn more at http://www.ExceptionalWomenAwardees.com

Share article on social media or email:

HA NOI, Vietnam (PRWEB)
May 26, 2020

The Novagen DNA testing center is built and developed by a team of experts with many years of experience in the fields of DNA Technology, Molecular Genetics, Genetic Analysis, Biochemistry, DNA Inspection, Genomics, Bioinformatics, Pharmaceuticals and Biomedical. The managing director of this center is Dr. Dang Tran Hoang, a doctorate graduate in biotechnology at the Kochi University of Technology from Japan, and a graduate of Hanoi University of Pharmacy. Dr. Dang Tran Hoang is an expert in the fields of Molecular Biology, Genetic Analysis, DNA Technology, genomic research and next-gen sequencing system (NGS).

DNA testing is the process of verifying a blood relationship between two people by comparing specific DNA markers in each person’s genome. This process allows Novagen to determine the blood relationship between relatives in the family, including father, child, mother, siblings, sisters, grandparents and grandchildren, uncle, aunt, niece, nephew. DNA testing is considered an integral part of administrative procedures, such as the process of accepting a father for a child, the procedure for making a birth certificate when the parents are not registered for marriage, the process of naturalization for children if dad is a foreigner.

Novagen is offering DNA testing services that focus on gene identification services, DNA testing, prenatal DNA testing, genetic testing and NIPT noninvasive prenatal screening. The Novagen testing laboratory is meeting the ISO 9001: 2015 standard and is the first company to apply 27 loci testing technology in DNA testing. The results are processed using the world’s latest DNA testing and analysis software (GeneMapper ID-X) and are approved by a scientific council of laboratory examiners.

“DNA testing technology has evolved to the extent that it can be widely used to address life’s problems such as verifying blood relationships, adopting an illegitimate son by a father, finding relatives, and screening for abnormalities. NIPT fetal defects.”, said Dr. Dang Tran Hoang, director of Novagen DNA center.

Novvagen is equipped with a comprehensive system of modern DNA analysis equipment imported from the USA, South Korea, and Europe such as aseptic clean room system, machine Techne (UK) 3PrimeX PCR, and Applied Biosystems ™ 3500 Series Genetic Analyzer. The staff is comprised of leading experts in Molecular Genetics, Biochemistry, Medicine who are committed to providing DNA testing services with accurate results, absolute reliability and confidentiality of customer information. A multi-step system that controls the entire process of DNA extraction and analysis has helped minimize the possibility of human error. To ensure accuracy, each test at the center is repeated 2 times.

Customers of Novagen can access various types of testing and services such as DNA tests for father and son, DNA test for the birth certificate, DNA tests for illegitimate son, prenatal DNA test, non-invasive fetal DNA test, DNA tests for mother and children, DNA testing for Bowel DNA, DNA tests for grandparents and grandchildren, DNA tests for relatives, screening for non-invasive birth defects, sequencing of new generation NGS gene.

At Novagen, they are always researching for innovation and they are constantly updated with the latest technological advances in DNA sequencing in the world. Customers of this center can choose to get their results in as little as 4 hours or they can choose to wait 2 days. Eager customers who want to quickly see their results will have to pay a fee of 6,000,000 VND if they want to get them in 4 hours or 5,000,000 VND if they can wait for 12 hours.

MEDIA CONTACT

Address 1: 68 Trung Kinh, Cau Giay, Ha Noi

Address 2: 112 Trung Kinh, Cau Giay, Ha Noi

Phone: 0987.666.081

Email: xetnghiemnovagen@gmail.com

Facebook: https://www.facebook.com/XetNghiemADN.NOVAGEN/

Behance: https://www.behance.net/hoangvnu

Pinterest: https://www.pinterest.com/hoangvnu/

Instagram: https://www.instagram.com/hoangvnu/

Share article on social media or email: